Show Notes
China’s biotech and healthcare sectors are evolving at extraordinary speed — from AI-powered “doctor avatars” and digital health super apps to a wave of Chinese drug innovation reshaping the global pharmaceutical industry. In this episode, I speak with physician and healthcare strategist Dr. Ruby Wang about the latest trends in China's AI + healthcare innovation.We discuss: Why Western pharma companies are rushing to license Chinese drugs China’s rise as a global biotech powerhouse AI doctors, digital hospitals, and health super apps The role of Alibaba, Ant Group, and DeepSeek in healthcare Why China’s healthcare digitization is moving faster than the West The future of AI in medicine and diagnosticsChinese medical devices, robotics, and healthcare hardware How Chinese regulators accelerated biotech innovation Whether healthcare can become China’s next major global export industry The challenges China still faces in healthcare access and inequality Ruby Wang is a UK-trained physician, founder of China Health Pulse, and author of the upcoming book China Cure, which explores the global impact of China’s biotech and AI healthcare advances. Links: China Health Pulse newsletter and podcast: https://www.chinahealthpulse.com/ For transcripts and more, check out the High Capacity newsletter: https://www.highcapacity.org/ More about the host, Kyle Chan: https://www.kyleichan.com/
More from High Capacity
China’s robots can dance and run marathons—but can they do useful work? And can China make the core components like actuators, reducers, and chips?
Can the US and China agree to slow down AI development—or even agree on what counts as an AI risk?
Is the U.S.–China AI competition really a winner-take-all race to AGI? Why has China embraced open-source AI? And are the biggest frontier models actually the greatest security threat? In this episode, I speak with Alvin Wang Graylin, a Digital Fellow at the Stanford Digital Economy Lab, a Senior Fellow at the Asia Society Policy Institute’s Center for China Analysis, a professor of AI and technology policy at the University of Washington, and co-author of Our Next Reality. We discuss: • China’s AI strategy and its focus on spreading AI throughout the economy • Why the “decisive strategic advantage” theory may misread the U.S.–China AI relationship • The prisoner’s dilemma, the stag hunt, and the case for cooperation on AI safety • China’s open-source AI ecosystem and the debate over open versus closed models • Why small, specialized AI systems may pose greater security risks than frontier models • How export controls may be accelerating Chinese AI innovation • China’s push into robotics, manufacturing, and physical AI • How China’s technology industry has changed over the past three decades Read Alvin’s essays, “Misdiagnosing the U.S.–China AI Race” and “The Biggest AI Models Are Not the Biggest Threats.” You can also follow Alvin on X and LinkedIn, or read his Substack, The Abundanist. For transcripts and more information, visit the High Capacity newsletter. Follow host Kyle Chan on X.
How do users in China get access to Claude and ChatGPT through the gray market? What’s really driving China’s apparent “AI optimism”? How is China trying to deal with deepfakes and AI-generated content?
How did China build a world-leading EV industry? China didn't just pick winners. Local governments and private entrepreneurs played a critical role alongside a broader national push into batteries and electric vehicle technology.